BioSpace News Archive

Business

Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates

Editas Medicine, Inc., a leading genome editing company, announced that it will host a conference call and webcast on Wednesday, August 3, 2022, at 8:00 a.m. ET to provide financial results and corporate updates for the second quarter of 2022.

July 26, 2022
·
1 min read
Drug Development

MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. announced the initiation of a Phase 2 clinical trial to evaluate MN-001 for the treatment of patients with non-alcoholic fatty liver disease, type 2 diabetes mellitus, and hypertriglyceridemia.

July 26, 2022
·
6 min read
Pharm Country

Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank

IVERIC bio, Inc. announced that it has entered into a term loan debt financing facility with Hercules Capital, Inc. and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-dilutive debt financing.

July 26, 2022
·
4 min read
Business

Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology.

July 26, 2022
·
3 min read
Business

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25.

July 26, 2022
·
4 min read
Drug Development

Instylla announces positive results from preclinical studies of Embrace™ Hydrogel Embolic System in hemorrhage models

Instylla, Inc. today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models.

July 26, 2022
·
3 min read
Lone Star Bio

Orthofix Announces First Clinical Use of Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

Orthofix Announces First Clinical Use of Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures.

July 26, 2022
·
6 min read
Business

Generate Biomedicines Expands Leadership Team with the Addition of Chief Medical Officer Alexandra Snyder, M.D.

Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Alexandra Snyder, M.D. has been named Chief Medical Officer.

July 26, 2022
·
4 min read
Dry Mouth Treatment Market: Competitive Landscape Analysis with Forecast by 2031

Wilmington, Delaware, United States, Transparency Market Research Inc.: The dry mouth treatment market is prognosticated to witness substantive growth owing to the rising prevalence of oral diseases among a major chunk of the global population.

July 26, 2022
·
6 min read
Drug Discovery Services Market is Expected to Witness Significant Growth between 2021–2031

Wilmington, Delaware, United States, Transparency Market Research Inc.: The drug discovery services market has been projected to grow at a noteworthy pace in the foreseeable years.

July 26, 2022
·
6 min read